Healthcare | May 05, 2026
OBESITAS 2026 concludes with focus on India’s rising obesity burden
The conference brought together over 500 doctors and 150 nutritionists to discuss emerging obesity-related challenges
The conference brought together over 500 doctors and 150 nutritionists to discuss emerging obesity-related challenges
The acquisition adds VYKAT XR (diazoxide choline), the first FDA-approved therapy for hyperphagia in Prader-Willi syndrome (PWS), a rare genetic disorder, to Neurocrine’s portfolio
Analysis of over 93 lakh preventive health checkups reveals disease risks emerging as early as the 20s
Searches for diabetes, heart conditions, and metabolism-related risks are rising sharply, with Tier 2 cities outpacing metros in specialist consultations
They stressed that while the drug is clinically proven to support weight and blood sugar control, it must be prescribed only after careful patient evaluation and used under strict medical supervision.
This study demonstrates the power of real-time glucose information for people with Type 2 diabetes treated with basal insulin
Diasens and GlucoLive are designed for diabetic, Chronic Kidney Disease (CKD), and post-transplant patients who require continuous glycaemic surveillance and integrated remote care
Strong performances in its Life Science, Healthcare and Electronics divisions — particularly Process Solutions, Cardiovascular treatments and Semiconductor Materials — powered the company’s results
The upcoming state-of-the art 400+ bed facility is set to come up at an approximate cost of Rs 500 crore
Subscribe To Our Newsletter & Stay Updated
